These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 16724093)

  • 1. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
    Chan T; Sami A; El-Gayed A; Guo X; Xiang J
    Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice.
    Sas S; Chan T; Sami A; El-Gayed A; Xiang J
    Cancer Gene Ther; 2008 Oct; 15(10):655-66. PubMed ID: 18421311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
    Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J
    Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
    Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
    Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12.
    Chen Y; Emtage P; Zhu Q; Foley R; Muller W; Hitt M; Gauldie J; Wan Y
    Gene Ther; 2001 Feb; 8(4):316-23. PubMed ID: 11313806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
    Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
    Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
    Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
    Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
    Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen.
    Song W; Tong Y; Carpenter H; Kong HL; Crystal RG
    Gene Ther; 2000 Dec; 7(24):2080-6. PubMed ID: 11223988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
    Liu Y; Zhang X; Zhang W; Chen Z; Chan T; Ali K; Jia Z; Xiang J
    Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
    Reilly RT; Gottlieb MB; Ercolini AM; Machiels JP; Kane CE; Okoye FI; Muller WJ; Dixon KH; Jaffee EM
    Cancer Res; 2000 Jul; 60(13):3569-76. PubMed ID: 10910070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y; Huang H; Chen Z; Zong L; Xiang J
    J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells pulsed with an anti-idiotype antibody mimicking Her-2/neu induced protective antitumor immunity in two lines of Her-2/neu transgenic mice.
    Saha A; Chatterjee SK
    Cell Immunol; 2010; 263(1):9-21. PubMed ID: 20236626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine.
    De Giovanni C; Nicoletti G; Landuzzi L; Astolfi A; Croci S; Comes A; Ferrini S; Meazza R; Iezzi M; Di Carlo E; Musiani P; Cavallo F; Nanni P; Lollini PL
    Cancer Res; 2004 Jun; 64(11):4001-9. PubMed ID: 15173014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
    Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
    Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine.
    Yo YT; Hsu KF; Shieh GS; Lo CW; Chang CC; Wu CL; Shiau AL
    Cancer Gene Ther; 2007 Nov; 14(11):904-17. PubMed ID: 17704754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination.
    Pupa SM; Invernizzi AM; Forti S; Di Carlo E; Musiani P; Nanni P; Lollini PL; Meazza R; Ferrini S; Menard S
    Gene Ther; 2001 Jan; 8(1):75-9. PubMed ID: 11402305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12.
    Okada N; Iiyama S; Okada Y; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A
    Cancer Gene Ther; 2005 Jan; 12(1):72-83. PubMed ID: 15389286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
    J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.